You are here

Roche

Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge

Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge

Bloomberg

Flag link:

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

Xconomy

Foundation Medicine

Flag link:

Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs

Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs

Endpoints

Flag link:

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

Endpoints

chronic lymphocytic leukemia

Flag link:

Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study

Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study

Fierce Pharma

multiple sclerosis

Flag link:

ASCO18: Who were the big winners and losers?

ASCO18: Who were the big winners and losers?

Biopharma Dive

Flag link:

Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage

Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage

Fierce Pharma

Flag link:

Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer

Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer

Endpoints

metastatic breast cancer

Flag link:

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

Biopharma Dive

advanced squamous non-small cell lung cancer

Flag link:

Roche scraps €120M SMA drug after hitting ‘many difficulties’

Roche scraps €120M SMA drug after hitting ‘many difficulties’

Fierce Biotech

spinal muscular atrophy

Flag link:

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Celltrion resubmits Rituxan candidate in US, Herceptin version to follow

Celltrion resubmits Rituxan candidate in US, Herceptin version to follow

Biopharma Reporter

Flag link:

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Endpoints

non-squamous non-small cell lung cancer

Bristol-Myers Squibb

Flag link:

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance

RAPS.org

Alzheimer's disease

Denali Therapeutics

Flag link:

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

Biopharma Dive

clinical trials

Flag link:

Roche drug dramatically reduces bleeds in key hemophilia tests

Roche drug dramatically reduces bleeds in key hemophilia tests

Reuters

clinical trials

Flag link:

Roche pens death notice for NewLink IDO/TDO cancer collaboration

Roche pens death notice for NewLink IDO/TDO cancer collaboration

Fierce Biotech

NewLink Genetics

IDO/TDO inhibitors

drug development

Flag link:

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

CP Wire

colorectal cancer

Flag link:

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

Flag link:

Pages